AxoGen, Inc.
Index- P/E- EPS (ttm)-0.69 Insider Own4.80% Shs Outstand42.22M Perf Week-0.81%
Market Cap470.66M Forward P/E- EPS next Y-0.44 Insider Trans-3.90% Shs Float39.38M Perf Month4.13%
Income-28.80M PEG- EPS next Q-0.11 Inst Own79.70% Short Float / Ratio1.38% / 2.16 Perf Quarter20.94%
Sales134.00M P/S3.51 EPS this Y-10.00% Inst Trans3.87% Short Interest0.54M Perf Half Y19.89%
Book/sh2.40 P/B4.62 EPS next Y-15.80% ROA-14.50% Target Price17.67 Perf Year9.69%
Cash/sh1.25 P/C8.86 EPS next 5Y- ROE-27.50% 52W Range6.87 - 13.66 Perf YTD18.36%
Dividend- P/FCF- EPS past 5Y-6.90% ROI-16.20% 52W High-18.81% Beta0.50
Dividend %- Quick Ratio3.50 Sales past 5Y25.40% Gross Margin80.30% 52W Low61.43% ATR0.64
Employees428 Current Ratio4.40 Sales Q/Q18.60% Oper. Margin-22.00% RSI (14)47.75 Volatility6.03% 6.28%
OptionableYes Debt/Eq0.45 EPS Q/Q40.60% Profit Margin-21.50% Rel Volume0.42 Prev Close11.03
ShortableYes LT Debt/Eq0.45 EarningsNov 08 BMO Payout- Avg Volume250.91K Price11.09
Recom1.70 SMA20-3.28% SMA50-2.93% SMA20015.39% Volume106,523 Change0.54%
Nov-11-22Resumed Jefferies Buy $15
May-09-22Upgrade Canaccord Genuity Hold → Buy $10 → $15
Mar-11-22Resumed Cantor Fitzgerald Overweight $21
Oct-23-20Initiated Guggenheim Buy $24
Jun-16-20Resumed Cantor Fitzgerald Overweight $16
May-07-20Downgrade Canaccord Genuity Buy → Hold $12
Apr-02-20Downgrade BTIG Research Buy → Neutral
Aug-07-19Downgrade William Blair Outperform → Mkt Perform
Jul-12-19Initiated Canaccord Genuity Buy $32
Mar-02-18Reiterated Lake Street Buy $26 → $38
Show Previous Ratings
Nov-11-22 08:50AM
Nov-08-22 08:15AM
Nov-03-22 04:00PM
07:00AM Loading…
Oct-31-22 07:00AM
Oct-27-22 12:00PM
Oct-20-22 07:00AM
Oct-19-22 09:40AM
Sep-29-22 05:32AM
Sep-22-22 09:55AM
Aug-08-22 09:55AM
Aug-03-22 05:25PM
04:01PM Loading…
Jul-29-22 07:00AM
Jul-25-22 08:24AM
Jul-20-22 03:26PM
Jul-18-22 04:00PM
Jul-11-22 07:00AM
May-25-22 07:12AM
May-18-22 07:00AM
May-05-22 10:58AM
May-04-22 07:45PM
Apr-15-22 09:33AM
Apr-13-22 07:00AM
Mar-17-22 07:00AM
06:15PM Loading…
Feb-22-22 06:15PM
Feb-16-22 10:54AM
Feb-15-22 03:01PM
Feb-14-22 05:20AM
Feb-03-22 07:00AM
Feb-02-22 07:00AM
Jan-10-22 07:00AM
Jan-04-22 07:00AM
Dec-16-21 05:19AM
Dec-15-21 11:39AM
Dec-09-21 03:06PM
Nov-10-21 07:00AM
Nov-04-21 07:00AM
Nov-03-21 09:31PM
Oct-27-21 03:03PM
Oct-17-21 08:40AM
Oct-13-21 07:00AM
Sep-22-21 07:00AM
Sep-01-21 07:00AM
Aug-18-21 06:35AM
Aug-05-21 04:30AM
Aug-04-21 05:55PM
Jul-28-21 03:03PM
Jul-22-21 07:00AM
Jul-19-21 04:01PM
Jul-14-21 07:00AM
Jun-19-21 03:24AM
May-18-21 08:43AM
May-07-21 08:56AM
May-06-21 07:00AM
May-05-21 05:15PM
Apr-28-21 12:34PM
Apr-20-21 02:06AM
Apr-14-21 07:00AM
Mar-01-21 04:01PM
Feb-22-21 04:01PM
Feb-19-21 10:16AM
Feb-18-21 11:47PM
Feb-04-21 07:00AM
Feb-01-21 07:00AM
Jan-11-21 07:00AM
Jan-05-21 07:00AM
Jan-04-21 11:22PM
Dec-23-20 07:00AM
Dec-15-20 10:17PM
Nov-06-20 05:38AM
Nov-04-20 07:00AM
Oct-30-20 02:31PM
Oct-29-20 06:55PM
Oct-28-20 10:15AM
Oct-08-20 07:00AM
Sep-30-20 04:01PM
Sep-25-20 07:00AM
Sep-24-20 07:00AM
Aug-31-20 07:00AM
Aug-07-20 09:48AM
Aug-05-20 07:45PM
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARIANI PETER JEVP & Chief Financial OfficerNov 16Sale11.8810,649126,51029,698Nov 18 05:53 PM
Freitag Gregory GeneDirectorNov 14Sale12.7413,000165,620339,583Nov 16 04:05 PM
Freitag Gregory GeneDirectorNov 08Sale12.5013,000162,500352,583Nov 10 04:09 PM
Freitag Gregory GeneDirectorAug 10Sale9.708,88686,159365,583Aug 11 09:50 PM
Freitag Gregory GeneDirectorAug 08Sale10.3713,046135,287374,469Aug 08 05:49 PM
Freitag Gregory GeneDirectorAug 04Sale10.6424,000255,360387,515Aug 08 05:49 PM
Freitag Gregory GeneDirectorJul 25Option Exercise3.3883,000280,540441,811Jul 26 08:42 PM
Levine Alan MDirectorJun 01Option Exercise0.003,036011,800Jun 03 04:15 PM
Ottinger BradleyGeneral Counsel and CCOJun 01Option Exercise0.0015,500018,573Jun 03 04:11 PM
NEELS GUIDO JDirectorJun 01Option Exercise0.003,036051,800Jun 03 04:09 PM
Wendell Amy McBrideDirectorJun 01Option Exercise0.003,036035,133Jun 03 04:09 PM
Freitag Gregory GeneDirectorJun 01Option Exercise0.003,0360358,811Jun 03 04:06 PM
Gold Mark StephenDirectorJun 01Option Exercise0.003,0360305,475Jun 03 04:07 PM
Blackford Quentin S.DirectorMar 30Option Exercise0.003,036027,335Apr 01 04:55 PM
MARTINEZ MARIA D.Chief Human Resources OfficerMar 16Option Exercise0.0012,866019,522Mar 18 04:14 PM
Zaderej Karen L.CEOMar 16Option Exercise0.0025,9500966,333Mar 18 04:12 PM
Scopelianos AngeloChief R&D OfficerMar 16Option Exercise0.0011,000022,950Mar 18 04:11 PM
Sandberg EricChief Commercial OfficerMar 16Option Exercise0.006,000014,310Mar 18 04:10 PM
MARIANI PETER JEVP & Chief Financial OfficerMar 16Option Exercise0.0011,000037,353Mar 18 04:07 PM
Friedman Mark LouisVP Regulatory Affairs & PolicyMar 16Option Exercise0.006,000025,845Mar 18 04:06 PM
Donovan Michael PatrickVP OperationsMar 16Option Exercise0.006,000063,453Mar 18 04:05 PM
DeVinney Erick WayneVP Peripheral Nerve ScienceMar 16Option Exercise0.006,000094,075Mar 18 04:03 PM
Billet IsabelleChief Strategy and BD OfficerMar 16Option Exercise0.008,500024,216Mar 18 04:01 PM
Donovan Michael PatrickVP OperationsFeb 22Option Exercise5.2115,00078,15057,453Feb 24 04:09 PM
Zaderej Karen L.CEODec 27Option Exercise0.004,4000927,429Dec 29 04:33 PM
Scopelianos AngeloChief R&D OfficerDec 27Option Exercise0.001,150011,270Dec 29 04:31 PM
MARTINEZ MARIA D.Chief Human Resources OfficerDec 27Option Exercise0.001,15006,017Dec 29 04:30 PM
MARIANI PETER JEVP & Chief Financial OfficerDec 27Option Exercise0.002,625024,794Dec 29 04:28 PM
Friedman Mark LouisVP Regulatory Affairs & PolicyDec 27Option Exercise0.001,150017,738Dec 29 04:23 PM
Donovan Michael PatrickVP OperationsDec 27Option Exercise0.001,150042,269Dec 29 04:21 PM
DeVinney Erick WayneVP Peripheral Nerve ScienceDec 27Option Exercise0.00750087,436Dec 29 04:17 PM
Billet IsabelleChief Strategy and BD OfficerDec 27Option Exercise0.001,150014,510Dec 29 04:15 PM
MARIANI PETER JEVP & Chief Financial OfficerDec 20Option Exercise0.001,900022,926Dec 22 04:07 PM
Zaderej Karen L.CEODec 20Option Exercise0.003,1250924,272Dec 22 04:09 PM
Friedman Mark LouisVP Regulatory Affairs & PolicyDec 20Option Exercise0.00375016,683Dec 22 04:06 PM
Donovan Michael PatrickVP OperationsDec 20Option Exercise0.00375041,214Dec 22 04:04 PM
DeVinney Erick WayneVP Peripheral Nerve ScienceDec 20Option Exercise0.00575086,830Dec 22 04:03 PM
DeVinney Erick WayneVP Peripheral Nerve ScienceDec 15Option Exercise3.6710,00036,70090,426Dec 17 04:02 PM